Trial reportCancer communications (London, England)2018
Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget's disease with curative responses.
Trial report in Cancer communications (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 72 citations in OpenAlex.
- Boron-10 carriers and their applications in boron neutron capture therapy.Precision radiation oncology · 2026Review
- Core clinical procedures and efficacy-enhancing strategies in boron neutron capture therapy.Discover oncology · 2026Review
- Advances in Clinical Trials of Boron Neutron Capture Therapy.Research (Washington, D.C.) · 2026Review
- Bystander and abscopal effects of boron neutron capture therapy: radiobiological mechanisms and immunotherapeutic strategies.Frontiers in oncology · 2026Review
- Biological evaluation of a glucose-based boron carrier as a potential agent for boron neutron capture therapy.International journal of cancer · 2025Article
- Boron carbide nanoparticles for boron neutron capture therapy.RSC advances · 2025Article
- Pregnancy Complicated by Rapidly Progressing Vulvar Melanoma: A Case Study.The American journal of case reports · 2025Article
- Boron neutron capture therapy for melanoma: recent advances and future prospects.Frontiers in oncology · 2025Review
- Cobaltabis(Dicarbollide) [Pharmaceuticals (Basel, Switzerland) · 2024Article
- Boron neutron capture therapy of cancer: where do we stand now?Cancer communications (London, England) · 2024Article
- Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT.Cancer communications (London, England) · 2024Review
- The current status and novel advances of boron neutron capture therapy clinical trials.American journal of cancer research · 2024Review
- Peptide Conjugated Boron Neutron Capture Therapy for Enhanced Tumor Targeting.Nanotheranostics · 2024Review
- Review
- Review
- Review
- Review
- Boron Neutron Capture Therapy: Clinical Application and Research Progress.Current oncology (Toronto, Ont.) · 2022Review
- The Anti-Tumor Effect of Boron Neutron Capture Therapy in Glioblastoma Subcutaneous Xenograft Model Using the Proton Linear Accelerator-Based BNCT System in Korea.Life (Basel, Switzerland) · 2022Article
- Boron Neutron Capture Therapy (BNCT) Mediated by Maleimide-FunctionalizedLife (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundAlthough the most commonly recommended treatment for melanoma and extramammary Paget's disease (EMPD) of the genital region is wide surgical excision of the lesion, the procedure is highly invasive and can lead to functional and sexual problems. Alternative treatments have been used for local control when wide local excision was not feasible. Here, we describe four patients with genital malignancies who were treated with boron neutron capture therapy (BNCT).
methodsThe four patients included one patient with vulvar melanoma (VM) and three with genital EMPD. They underwent BNCT at the Kyoto University Research Reactor between 2005 and 2014 using para-boronophenylalanine as the boron delivery agent. They were irradiated with an epithermal neutron beam between the curative tumor dose and the tolerable skin/mucosal doses.
resultsAll patients showed similar tumor and normal tissue responses following BNCT and achieved complete responses within 6 months. The most severe normal tissue response was moderate skin erosion during the first 2 months, which diminished gradually thereafter. Dysuria or contact pain persisted for 2 months and resolved completely by 4 months.
conclusionsTreating VM and EMPD with BNCT resulted in complete local tumor control. Based on our clinical experience, we conclude that BNCT is a promising treatment for primary VM and EMPD of the genital region. Trial registration numbers UMIN000005124.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.